Skip to main content
Premium Trial:

Request an Annual Quote

Admera Liquid Biopsy Testing

Admera Health has announced the imminent launch of its liquid biopsy cancer test using the company's proprietary BEST blocker enrichment technology. The test involved identify the BRAF V600 tumor mutation frequently found in melanoma and also observed in non-small cell lung cancer, colorectal cancer, papillary thyroid cancer, ovarian cancer, glioma, and gastrointestinal stromal tumor. The BEST technology can reliably isolate and amplify circulating cell-free tumor DNA fragments in the bloodstream and then identify actionable genetic mutations, using next generation sequencing technology and advanced bioinformatics analysis systems. The test will be run through the company's New Jersey-based, CLIA approved laboratory.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.